COPD patients expressing the highest baseline CRP or TNF-alpha levels also did not demonstrate a significant impact of infliximab on changes from baseline in clinical and biomarker measurements, unlike results recently reported for sarcoidosis [21]. Here, CRP is linked to sarcoidosis.